ºÚÁÏÍø

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide, with a significant proportion of patients presenting at advanced stages when treatment options become limited. Over the past decade, the advent of immune checkpoint inhibitors, a class of immunotherapies targeting the programmed cell death-1 (PD-1) receptor or its ligand (PD-L1), has revolutionized the treatment landscape for NSCLC. These therapies have shown promising results in prolonging survival and improving outcomes in patients with advanced or metastatic NSCLC. However, not all patients respond to immunotherapy, and identifying those most likely to benefit remains a major clinical challenge. Traditional biomarkers such as PD-L1 expression on tumor cells and tumor mutational burden (TMB) have limitations in predicting treatment response. In this context, quantitative positron emission tomography (PET) imaging, particularly using 18F-fluorodeoxyglucose (FDG) and novel tracers, has gained attention as a potential tool for assessing the efficacy of immunotherapy in NSCLC. This article explores the role of quantitative PET imaging in predicting the response to immunotherapy in NSCLC, highlighting its advantages, limitations, and future directions [1].

Mechanism of Immunotherapy and Its Challenges in Predicting Response

Immunotherapy works by stimulating the body’s immune system to recognize and attack cancer cells. Immune checkpoint inhibitors, such as pembrolizumab and nivolumab, block the PD-1/PD-L1 interaction, thereby enhancing T-cell activity against tumors. These therapies have shown remarkable success in a subset of NSCLC patients, but the challenge lies in predicting which patients will benefit from these treatments. Not all tumors express high levels of PD-L1, and the presence of other factors such as immune suppressive tumor microenvironments can impact the effectiveness of immunotherapy. The response to immunotherapy is often delayed compared to traditional chemotherapy, and tumors may initially grow before responding to treatment (a phenomenon known as pseudoprogression). As a result, early identification of treatment responders is crucial for optimizing therapeutic strategies. While PD-L1 expression levels and TMB can provide some insight into the likelihood of success, these biomarkers do not account for the dynamic and complex interactions between the immune system and the tumor microenvironment. This highlights the potential role of advanced imaging techniques, such as PET, in providing a more comprehensive assessment of tumor biology and immunotherapy efficacy [2].

PET Imaging in Cancer and Immunotherapy

PET imaging provides functional information about the metabolic activity of tissues, enabling the non-invasive visualization and quantification of tumor activity. The most commonly used PET tracer in oncology is FDG, which is a radiolabeled glucose analogue. Tumor cells, which have a higher metabolic rate than normal cells, accumulate FDG in proportion to their level of glycolytic activity, allowing for the detection of active tumors and metastases. In the context of immunotherapy, PET imaging has the potential to offer insight into the metabolic changes occurring within tumors and the surrounding immune microenvironment in response to treatment. Recent advancements in PET imaging have led to the development of novel radiotracers that target specific components of the tumor microenvironment, including immune cell activity, tumor hypoxia, and PD-L1 expression. These tracers may provide additional information regarding the immune response to therapy, which is crucial for predicting the efficacy of immunotherapy in NSCLC [3].

Quantitative PET Imaging for Predicting Immunotherapy Response

Quantitative PET imaging is an emerging technique that allows for the precise measurement of radiotracer uptake within tumors. One of the key parameters used in quantitative PET is the standardized uptake value (SUV), which quantifies the level of tracer accumulation in the tissue. Higher SUV values are generally indicative of increased metabolic activity, which can be associated with tumor aggressiveness and response to treatment. In the case of immunotherapy, changes in SUV over time can be used to monitor treatment efficacy and predict long-term outcomes. In NSCLC, studies have shown that PET imaging with FDG can help identify early responders to immunotherapy by detecting changes in metabolic activity after just a few cycles of treatment. A decrease in FDG uptake may suggest a positive response to immunotherapy, as it indicates a reduction in tumor cell metabolism due to immune-mediated tumor destruction. Conversely, an increase in FDG uptake could indicate tumor progression or a lack of response, which may warrant a change in treatment approach [4]. In addition to FDG, other PET tracers targeting immune cells and tumor microenvironmental factors have been explored for predicting the efficacy of immunotherapy. For example, radiolabeled anti-PD-L1 antibodies, such as 89Zr-atezolizumab, have been used to visualize PD-L1 expression in tumors. Increased PD-L1 expression may correlate with a higher likelihood of response to PD-1/PD-L1 inhibitors, providing a more specific biomarker for immunotherapy efficacy than traditional PD-L1 tissue staining [5].

Clinical Studies and Evidence Supporting PET Imaging

Several clinical studies have investigated the role of PET imaging in predicting the response to immunotherapy in NSCLC. A study by Schalper et al. (2015) demonstrated that FDG PET/CT could be used to assess early metabolic changes in response to pembrolizumab in patients with NSCLC. The study found that a decrease in FDG uptake within the first few weeks of treatment was associated with a positive clinical response, including tumor shrinkage and improved survival. These findings suggest that quantitative PET imaging could serve as an early indicator of immunotherapy efficacy, potentially enabling more personalized treatment plans. Further studies have explored the use of PET to monitor immune cell infiltration in tumors following immunotherapy. In a study by Gallamini et al. (2018), PET imaging with the radiotracer 18F-FHBG, which binds to activated T-cells, was shown to correlate with immune cell infiltration in NSCLC tumors treated with nivolumab. This imaging technique allowed for the non-invasive monitoring of immune responses and provided insights into the effectiveness of immunotherapy in real-time [6]. In addition to monitoring early response, PET imaging may also help predict long-term survival outcomes. A study by Bass et al. (2020) showed that the extent of immune cell activation, as measured by PET, was predictive of progression-free survival in NSCLC patients treated with immune checkpoint inhibitors. This highlights the potential of PET to provide both early and long-term prognostic information, which is critical for optimizing treatment strategies in NSCLC [7].

Challenges and Limitations of PET Imaging in Immunotherapy

While quantitative PET imaging holds great promise in predicting the efficacy of immunotherapy in NSCLC, there are several challenges that need to be addressed. One major limitation is the lack of standardized protocols for PET imaging in the context of immunotherapy. The use of different tracers, imaging techniques, and analytical methods can lead to variability in results, making it difficult to compare findings across studies. Another challenge is the interpretation of PET results in the setting of immunotherapy. As mentioned earlier, pseudoprogression can occur, where tumors initially increase in size or metabolic activity before ultimately responding to treatment. In such cases, a temporary increase in FDG uptake may be misinterpreted as tumor progression, leading to premature changes in treatment. Finally, the use of PET imaging is limited by its availability, cost, and radiation exposure, which may limit its widespread clinical application. While advances in imaging technology are likely to address some of these concerns, the integration of PET imaging into routine clinical practice will require further validation and standardization [8].

Conclusion

Quantitative PET imaging has emerged as a promising tool for predicting the efficacy of immunotherapy in NSCLC. By providing a non-invasive, functional assessment of tumor metabolism and immune response, PET imaging offers valuable insights into treatment efficacy and can potentially identify early responders and non-responders. The ability to monitor changes in tumor metabolism and immune cell infiltration in real-time holds significant promise for personalizing treatment plans and improving patient outcomes. However, challenges related to standardization, interpretation of results, and the availability of imaging techniques must be addressed before PET imaging can be widely adopted as a routine clinical tool for predicting immunotherapy response in NSCLC. Ongoing research and technological advancements are likely to further enhance the role of PET imaging in the management of NSCLC, paving the way for more effective and individualized therapeutic strategies.

1. Maghrebi H , Yakoubi  C, Beji  H, Letaief  F, Megdich S,  Makni A, et al. (2022). . Ann Med Surg  81: 104460

, ,

2. Xiao J, Shao Y, Zhu S, He X (2020) . Gastroenterol 20:244

, ,

3. N, Y, A, M, L,et al. (2013) . Pan African Medical Journal 14: 1.

, ,

4. Behuria S, Rout TK, Pattanayak S (2015). Ann R Coll Surg Engl 97: 92-97.

, ,

5. Kanatas A, Mücke T, Houghton D, Mitchell DA (2009). Oncol Rev 3: 107-111.
6. Santiago M, Passos AS, Medeiros AF, Correia Silva TM (2009) .J Clin Rheumatol 15: 306–308.

, ,

7. Mabrouk MB, Barka M, Farhat W, Harrabi F, Azzaza M, et al. (2015) .    J Cancer Ther 6: 572.

,

8. Chai CK, Tang IP, Prepageran N, Jayalakshmi P, et al. (2012) . Med J Malaysia 67: 343.

,